RxDoctor Payments Data

Stephanie Clapper, MD

Family Medicine · East Syracuse, NYNPI 1578718730

Payments from drug & device makers

$8,776in general payments, 2019–2025

Across 623 payments — averaging $14.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$998
  • Novo Nordisk$842
  • AstraZeneca$787
  • GSK$689
  • Amgen$493
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$8,744100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,776 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$164,597
Medicare patients
335
Services billed
4,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide91$155,655
JardianceEmpagliflozin86$120,501
MounjaroTirzepatide44$88,269
OzempicSemaglutide57$77,956
EliquisApixaban51$56,923
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$52,371
RybelsusSemaglutide17$38,066
MyrbetriqMirabegron29$28,418
XareltoRivaroxaban12$20,189
LinzessLinaclotide15$19,378
ProliaDenosumab11$19,206
GlatopaGlatiramer Acetate12$16,921
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$9,611
Levothyroxine Sodium474$6,569
Atorvastatin Calcium533$5,799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$77$243,924135 claims
Boehringer IngelheimJardiance$227$120,50186 claims
Novo NordiskOzempic, Rybelsus$842$116,02274 claims
PfizerEliquis, Prempro$998$59,77663 claims
GSKTrelegy Ellipta$689$52,37161 claims
Astellas Pharma US IncMyrbetriq$139$28,41829 claims
AbbVieLinzess, Synthroid$1,709$24,74184 claims
Johnson & JohnsonXarelto$342$20,18912 claims
AmgenProlia$493$19,20611 claims
MerckBelsomra$74$5,70613 claims
AstraZenecaNexium$787$3,20512 claims
Almatica Pharma LLCSertraline Hcl$34$2,331235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in East Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →